Day One Biopharmaceuticals, Inc. Financials
This page shows Day One Biopharmaceuticals, Inc. (DAWN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has started to scale, but the company still runs on an equity-funded research spend model.
FY2025 shows a different loss engine: revenue grew20.6% while operating loss narrowed41.2% , and with R&D spending lower but SG&A slightly higher, that improvement came from reduced development intensity more than from sales absorbing overhead. Operating cash flow of-$104M was nearly identical to free cash flow of-$104M , which signals an asset-light burn profile where cash use is driven by expensed operations, not capital equipment.
The balance sheet is still cash-heavy: cash of
Combined R&D plus SG&A reached
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Day One Biopharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Day One Biopharmaceuticals, Inc. has an operating margin of -80.8%, meaning the company retains $-81 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -165.7% the prior year.
Day One Biopharmaceuticals, Inc. carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.02, Day One Biopharmaceuticals, Inc. holds $8.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Day One Biopharmaceuticals, Inc. generated -$103.8M in operating cash flow, capex of $320K consumed most of it, leaving -$104.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Day One Biopharmaceuticals, Inc. passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Day One Biopharmaceuticals, Inc. generated $158.2M in revenue in fiscal year 2025. This represents an increase of 20.6% from the prior year.
Day One Biopharmaceuticals, Inc.'s EBITDA was -$127.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.3% from the prior year.
Day One Biopharmaceuticals, Inc. earned $-1.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2.0% from the prior year.
Cash & Balance Sheet
Day One Biopharmaceuticals, Inc. generated -$104.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 29.6% from the prior year.
Day One Biopharmaceuticals, Inc. held $197.1M in cash against $0 in long-term debt as of fiscal year 2025.
Day One Biopharmaceuticals, Inc. had 103M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.
Margins & Returns
Day One Biopharmaceuticals, Inc.'s operating margin was -80.8% in fiscal year 2025, reflecting core business profitability. This is up 84.9 percentage points from the prior year.
Capital Allocation
Day One Biopharmaceuticals, Inc. invested $148.1M in research and development in fiscal year 2025. This represents a decrease of 34.9% from the prior year.
Day One Biopharmaceuticals, Inc. invested $320K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 85.2% from the prior year.
DAWN Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M+35.0% | $39.8M+17.4% | $33.9M+10.2% | $30.8M | N/A | $93.8M+1044.5% | $8.2M | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $40.9M+30.3% | $31.4M-13.1% | $36.1M-8.8% | $39.6M | N/A | $33.6M-63.6% | $92.1M+129.1% | $40.2M |
| SG&A Expenses | $34.1M+21.3% | $28.1M-2.8% | $29.0M-1.2% | $29.3M | N/A | $29.0M-4.0% | $30.2M+13.7% | $26.6M |
| Operating Income | -$27.5M-13.2% | -$24.3M+30.7% | -$35.0M+14.8% | -$41.1M | N/A | $29.6M+125.8% | -$114.8M-72.0% | -$66.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$2.0M | $0 | $0 | $0 | N/A | -$882K-156.8% | $1.6M | $0 |
| Net Income | N/A | -$19.7M+34.9% | -$30.3M+15.8% | -$36.0M | N/A | $37.0M+940.4% | -$4.4M+92.9% | -$62.4M |
| EPS (Diluted) | N/A | $-0.19+34.5% | $-0.29+17.1% | $-0.35 | N/A | $0.38+860.0% | $-0.05+93.1% | $-0.72 |
DAWN Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $507.8M-1.2% | $513.8M-1.0% | $519.0M-2.9% | $534.4M-8.3% | $582.8M-3.0% | $600.8M+50.0% | $400.4M+22.6% | $326.6M |
| Current Assets | $485.1M-1.0% | $490.0M-0.9% | $494.4M-2.8% | $508.7M-9.5% | $562.3M-3.2% | $581.0M+51.6% | $383.2M+17.5% | $326.0M |
| Cash & Equivalents | $197.1M+355.4% | $43.3M+21.5% | $35.6M+6.8% | $33.4M-73.3% | $125.0M-70.4% | $422.8M+76.4% | $239.6M-11.4% | $270.4M |
| Inventory | $6.3M-10.4% | $7.1M+7.9% | $6.5M+83.5% | $3.6M+7.3% | $3.3M+21.4% | $2.7M+1711.3% | $151K | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $66.7M+6.0% | $62.9M+8.1% | $58.2M+6.1% | $54.8M-31.5% | $80.0M+76.5% | $45.3M-51.6% | $93.7M+214.0% | $29.8M |
| Current Liabilities | $60.5M+7.2% | $56.5M+10.2% | $51.2M+7.0% | $47.9M-34.8% | $73.5M+84.8% | $39.7M-57.6% | $93.7M+214.0% | $29.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $441.2M-2.2% | $450.9M-2.2% | $460.8M-3.9% | $479.5M-4.6% | $502.8M-9.5% | $555.5M+81.1% | $306.7M+3.3% | $296.8M |
| Retained Earnings | -$661.4M-3.3% | -$640.1M-3.2% | -$620.4M-5.1% | -$590.1M-6.5% | -$554.1M-13.5% | -$488.4M+7.0% | -$525.4M-0.8% | -$521.0M |
DAWN Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.1M-143.7% | -$5.8M+76.6% | -$24.8M+58.0% | -$59.0M-96.6% | -$30.0M-159.1% | $50.8M+203.3% | -$49.1M+1.2% | -$49.7M |
| Capital Expenditures | $0 | $0-100.0% | $3K-99.1% | $317K-77.7% | $1.4M+96.0% | $724K+2684.6% | $26K | $0 |
| Free Cash Flow | -$14.1M-143.7% | -$5.8M+76.6% | -$24.8M+58.2% | -$59.3M-88.7% | -$31.4M-162.8% | $50.0M+201.8% | -$49.2M+1.2% | -$49.7M |
| Investing Cash Flow | $167.5M+1144.3% | $13.5M-48.9% | $26.3M+180.7% | -$32.6M+87.9% | -$269.6M-298.3% | -$67.7M-496.9% | $17.1M-80.9% | $89.3M |
| Financing Cash Flow | $471K | $0-100.0% | $748K | $0-100.0% | $1.9M-99.1% | $200.1M+15327.5% | $1.3M+2602.1% | $48K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DAWN Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -51.1%+9.8pp | -60.9%+42.2pp | -103.1%+30.4pp | -133.5% | N/A | 31.6%+1433.1pp | -1401.5% | N/A |
| Net Margin | N/A | -49.6%+39.9pp | -89.4%+27.6pp | -117.0% | N/A | 39.5%+93.3pp | -53.8% | N/A |
| Return on Equity | N/A | -4.4%+2.2pp | -6.6%+0.9pp | -7.5% | N/A | 6.7%+8.1pp | -1.4%+19.6pp | -21.0% |
| Return on Assets | N/A | -3.8%+2.0pp | -5.8%+0.9pp | -6.7% | N/A | 6.2%+7.3pp | -1.1%+18.0pp | -19.1% |
| Current Ratio | 8.02-0.7 | 8.68-1.0 | 9.65-1.0 | 10.62+3.0 | 7.66-7.0 | 14.62+10.5 | 4.09-6.8 | 10.93 |
| Debt-to-Equity | 0.15+0.0 | 0.14+0.0 | 0.13+0.0 | 0.11-0.0 | 0.16+0.1 | 0.08-0.2 | 0.31+0.2 | 0.10 |
| FCF Margin | -26.3%-11.8pp | -14.6%+58.6pp | -73.2%+119.6pp | -192.8% | N/A | 53.4%+653.4pp | -600.0% | N/A |
Similar Companies
Frequently Asked Questions
What is Day One Biopharmaceuticals, Inc.'s annual revenue?
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in total revenue for fiscal year 2025. This represents a 20.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Day One Biopharmaceuticals, Inc.'s revenue growing?
Day One Biopharmaceuticals, Inc. (DAWN) revenue grew by 20.6% year-over-year, from $131.2M to $158.2M in fiscal year 2025.
What is Day One Biopharmaceuticals, Inc.'s EBITDA?
Day One Biopharmaceuticals, Inc. (DAWN) had EBITDA of -$127.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Day One Biopharmaceuticals, Inc.'s operating margin?
Day One Biopharmaceuticals, Inc. (DAWN) had an operating margin of -80.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Day One Biopharmaceuticals, Inc.'s free cash flow?
Day One Biopharmaceuticals, Inc. (DAWN) generated -$104.1M in free cash flow during fiscal year 2025. This represents a -29.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Day One Biopharmaceuticals, Inc.'s operating cash flow?
Day One Biopharmaceuticals, Inc. (DAWN) generated -$103.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Day One Biopharmaceuticals, Inc.'s total assets?
Day One Biopharmaceuticals, Inc. (DAWN) had $507.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Day One Biopharmaceuticals, Inc.'s capital expenditures?
Day One Biopharmaceuticals, Inc. (DAWN) invested $320K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Day One Biopharmaceuticals, Inc. spend on research and development?
Day One Biopharmaceuticals, Inc. (DAWN) invested $148.1M in research and development during fiscal year 2025.
What is Day One Biopharmaceuticals, Inc.'s current ratio?
Day One Biopharmaceuticals, Inc. (DAWN) had a current ratio of 8.02 as of fiscal year 2025, which is generally considered healthy.
What is Day One Biopharmaceuticals, Inc.'s debt-to-equity ratio?
Day One Biopharmaceuticals, Inc. (DAWN) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Day One Biopharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Day One Biopharmaceuticals, Inc. (DAWN) had $197.1M in cash against an annual operating cash burn of $103.8M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Day One Biopharmaceuticals, Inc.'s Piotroski F-Score?
Day One Biopharmaceuticals, Inc. (DAWN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Day One Biopharmaceuticals, Inc.?
Day One Biopharmaceuticals, Inc. (DAWN) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.